Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA Damage Response.
Dr. Gilad has extensive leadership experience across all phases of drug development. He has an accomplished track record leading Atrin from inception to pre-clinical and moving into the clinical stage. Prior to founding Atrin in 2011, Dr. Gilad had a 13-year academic career, where he has authored numerous high impact scientific articles, including one that demonstrated the importance of the ATR pathway in cancer development and prevention. This breakthrough research was conducted at the University of Pennsylvania. This is the third company that he has set up, the first two having been sold.
Oren Gilad, Ph.D - President and CEO
Dr. Gilad holds a B.Sc from the Hebrew University, a Ph.D and post-doctorate from University of California at Davis, and a post-doctorate from the University of Pennsylvania.